Does the literature support an indication for hepatic metastasectomy other than for colorectal primary?
Hepatic resection for colorectal hepatic metastatic disease has been demonstrated to have a significant outcome benefit for selected patients. Advances in anesthetic and surgical technique have resulted in a significantly reduced morbidity and mortality for this procedure, and this management approach has become widely practiced. This hepatic resection paradigm is also being applied to hepatic metastatic disease of noncolorectal origin. The purpose of this report is to review and summarize the reported literature in order to define if the current data support an indication for hepatic metastasectomy. The specific cancer primaries that this analysis evaluated include breast, melanoma, gynecologic, neuroendocrine, sarcoma, and gastric cancer. Based on the data examined, we propose that although hepatic metastasectomy for noncolorectal cancer may be a promising component of overall oncologic treatment, the role of surgical resection cannot be generalized and at present should be individualized based on the patient's clinical course and by the biologic behaviors of specific malignancies.
Alseidi
Adnan
A
Department of Surgery, University of Illinois at Chicago, 60612, USA.
Helton
W Scott
WS
Espat
N Joseph
NJ
D001943:Breast Neoplasms / Q000473:pathology; D003110:Colonic Neoplasms / Q000473:pathology*; D005260:Female; D005833:Genital Neoplasms, Female / Q000473:pathology; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery; D008545:Melanoma / Q000556:secondary; D018358:Neuroendocrine Tumors / Q000556:secondary; D012004:Rectal Neoplasms / Q000473:pathology*; D012509:Sarcoma / Q000556:secondary; D013274:Stomach Neoplasms / Q000473:pathology